These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 10164060)

  • 21. ACE inhibitors: review of four new agents.
    Binder SB
    Am Fam Physician; 1993 Oct; 48(5):851-7. PubMed ID: 8213415
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does the duration of action of angiotensin converting enzyme inhibitors affect their safety and adverse effects?
    Frank GJ
    J Hypertens Suppl; 1989 Sep; 7(5):S17-22. PubMed ID: 2553900
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current indications for ACE inhibitors and HOPE for the future.
    Burch S; Ou N
    Am J Manag Care; 2002 May; 8(5):478-90; quiz 491-3. PubMed ID: 12019599
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Choosing the right ACE inhibitor. A guide to selection.
    Leonetti G; Cuspidi C
    Drugs; 1995 Apr; 49(4):516-35. PubMed ID: 7789286
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Who should be treated with angiotensin-converting enzyme inhibitors after myocardial infarction?
    Ball SG; Hall AS
    Am Heart J; 1996 Jul; 132(1 Pt 2 Su):244-50. PubMed ID: 8677863
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ramipril for the prevention and treatment of cardiovascular disease.
    Vuong AD; Annis LG
    Ann Pharmacother; 2003 Mar; 37(3):412-9. PubMed ID: 12639174
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ACE inhibitors and the kidney. A risk-benefit assessment.
    Navis G; Faber HJ; de Zeeuw D; de Jong PE
    Drug Saf; 1996 Sep; 15(3):200-11. PubMed ID: 8879974
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Do converting enzyme inhibitors differ from each other in the treatment of hypertension?].
    Laurent S; Billaud E; Kreft-Jais C
    Rev Prat; 1992 Dec; 42(20):2533-7. PubMed ID: 1299936
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic optimisation of angiotensin converting enzyme (ACE) inhibitor therapy.
    Burnier M; Biollaz J
    Clin Pharmacokinet; 1992 May; 22(5):375-84. PubMed ID: 1505143
    [TBL] [Abstract][Full Text] [Related]  

  • 31. What is the role of angiotensin-converting enzyme inhibitors in congestive heart failure and after myocardial infarction?
    Nelson KM; Yeager BF
    Ann Pharmacother; 1996 Sep; 30(9):986-93. PubMed ID: 8876861
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The value of angiotensin-converting enzyme inhibitors in the treatment of hypertension].
    Klaus D
    Z Kardiol; 1988; 77 Suppl 3():73-88. PubMed ID: 3062960
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trandolapril. An update of its pharmacology and therapeutic use in cardiovascular disorders.
    Peters DC; Noble S; Plosker GL
    Drugs; 1998 Nov; 56(5):871-93. PubMed ID: 9829159
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Spirapril. A preliminary review of its pharmacology and therapeutic efficacy in the treatment of hypertension.
    Noble S; Sorkin EM
    Drugs; 1995 May; 49(5):750-66. PubMed ID: 7601014
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk-benefit ratio of angiotensin antagonists versus ACE inhibitors in end-stage renal disease.
    Sica DA; Gehr TW; Fernandez A
    Drug Saf; 2000 May; 22(5):350-60. PubMed ID: 10830252
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Comparative evaluation of ACE inhibitors: which differences are relevant?].
    Fischler MP; Follath F
    Schweiz Med Wochenschr; 1999 Jul; 129(29-30):1053-60. PubMed ID: 10464907
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Choosing a first-line drug in the management of elevated blood pressure: what is the evidence? 3: Angiotensin-converting-enzyme inhibitors.
    Wright JM
    CMAJ; 2000 Aug; 163(3):293-6. PubMed ID: 10951729
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacoeconomic considerations in assessing and selecting congestive heart failure therapies.
    Levy E; Levy P
    Pharmacoeconomics; 2002; 20(14):963-77. PubMed ID: 12403637
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.